Table 4.

Effects of TNF-α inhibitor treatment on lipid profile: stratification analysis by statin use

		No statins		Statin treatment begun after initiating TNF-α inhibitor treatment		Statin treatment begun before and continued during TNF-α inhibitor treatment
	Time period	Mean ± standard error	p value	Mean ± standard error	p value	Mean ± standard error	p value
Total cholesterola (mg/dl)	Reference	183.73 ± 3.26		188.96 ± 8.92		182.04 ± 5.65
	0–6 months	188.63 ± 3.42	0.007	208.22 ± 9.02	0.005	188.78 ± 5.73	NS
	6–12 months	185.20 ± 3.29	NS	197.92 ± 8.74	NS	184.05 ± 5.60	NS
	12–18 months	187.77 ± 3.22	0.03	198.55 ± 9.15	0.04	180.42 ± 5.48	NS
	18–24 months	188.62 ± 3.34	NS	199.38 ± 8.46	0.01	178.89 ± 5.14	NS
LDLa (mg/dl)	Reference	103.13 ± 3.68		112.10 ± 5.62		119.97 ± 2.86
	0–6 months	106.01 ± 3.83	0.057	123.42 ± 7.62	0.05	107.84 ± 3.96	<0.001
	6–12 months	105.63 ± 3.80	NS	115.35 ± 7.05	NS	108.26 ± 4.07	<0.001
	12–18 months	106.85 ± 3.80	0.02	119.67 ± 6.38	0.03	101.85 ± 3.57	<0.001
	18–24 months	107.70 ± 3.76	0.001	115.89 ± 6.81	NS	104.02 ± 3.57	<0.001
Triglyceridesa (mg/dl)	Reference	119.41 ± 9.75		179.31 ± 19.96		142.14 ± 9.89
	0–6 months	134.33 ± 10.24	<0.001	223.91 ± 24.84	0.002	147.33 ± 10.67	NS
	6–12 months	128.80 ± 10.05	0.02	186.09 ± 20.47	NS	145.81 ± 10.15	NS
	12–18 months	135.89 ± 10.19	0.001	181.31 ± 20.98	NS	149.60 ± 10.16	NS
	18–24 months	135.99 ± 10.20	<0.001	194.68 ± 23.42	NS	146.72 ± 10.82	NS

^aAdjusted for hyperlipidemia, hypertension, obesity, gender, and age

TNF-α tumor necrosis factor alpha, LDL low-density lipoprotein, NS not significant